EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2022

Feb. 3, 2013 - PRLog -- Lifestyle factors, including a sedentary lifestyle and high caloric and alcohol intake are contributing to an increase in prevalent cases of dyslipidemia across India, says research and consulting firm GlobalData.

The company’s new epidemiology report* forecasts the number of dyslipidemia sufferers across the south Asian nation to climb from 192.7 million in 2012 to 245 million by the end of 2022 – a growth of 27% in just 10 years. GlobalData attributes this jump in prevalent cases primarily to the expected continuation of healthy population growth.

The nation with the second largest increase across the nine countries studied in the report, China, is predicted to increase by a comparatively modest 15% during the same period – from 84.7 million prevalent cases in 2012 to 97.1 million a decade on.

For Sample Pages, please click or add the below link to your browser:

http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/EpiCast-Report-Dyslipidemia-Epidemiology-Forecast-to-2022/sample&CompanyID=prlog

GlobalData’s epidemiologists forecast that the prevalent cases of dyslipidemia in the nine major markets (the US, China, Japan, India and the five top European markets) will increase from 444 million cases in 2012 to 522 million cases in 2022 at an Annual Growth Rate (AGR) of 1.76%.

This report provides an overview of the risk factors and global trends of dyslipidemia in seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan) in addition to two emerging markets—India and China.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.

For further details, please click or add the below link to your browser:

http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/EpiCast-Report-Dyslipidemia-Epidemiology-Forecast-to-2022&CompanyID=prlog (http://store.globaldata.com/market-reports/pharmaceutical...)

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:

pressreleases@globaldata.com

North America:          +1 646 395 5477

Europe:          +44 207 753 4299

         +44 1204 543 533

Asia Pacific:          +91 40 6616 6782